Researchers discussed the potential impact of a dual GLP‑1/glucagon receptor agonist on patients with obesity‑related liver disease during a recent medical webcast titled “Translating SYNCHRONIZE‑1 to Practice: Who May Benefit From Dual GLP‑1/Glucagon Receptor Agonism?”
Phase 2 data suggest histologic benefits
Dr. Mazen Noureddin, a hepatology specialist, referenced Phase 2 trial results for the investigational drug survodutide, which were published in the New England Journal of Medicine. The study reported improvements in steatohepatitis histology and a notable reduction in fibrosis. He highlighted that magnetic resonance imaging–based proton density fat fraction (MRI‑PDFF) declines have been linked to histologic gains in steatohepatitis and fibrosis. The reductions in liver fat observed in the SYNCHRONIZE‑1 trial could serve as a predictive surrogate for the histologic outcomes being examined in the ongoing Phase 3 LEVERAGE and LEVERAGE Cirrhosis studies.
Patient groups likely to see the greatest gains
According to the discussion, individuals with obesity who also have liver disease are the most promising candidates for this therapy. The dual agonist’s profile includes significant weight loss, visceral fat reduction, preservation of lean muscle, and normalization of hepatic fat. Noureddin noted that such a “holistic” effect may appeal to patients whose metabolic load extends beyond the liver, offering a single agent that tackles multiple drivers of disease.
Weight loss alone can improve liver outcomes, but the combination of GLP‑1 and glucagon receptor activation could amplify those benefits. The conversation highlighted that the magnitude of liver fat reduction seen in SYNCHRONIZE‑1 aligns with the surrogate markers used to predict histologic response.
Related: Users Report Website Access Blocks
While the data are still pending FDA approval, the potential for a therapy that addresses both obesity and liver pathology in one package is compelling for clinicians managing complex metabolic patients.
Trial design includes diverse endpoints, ranging from imaging biomarkers to biopsy‑based assessments, which should provide a clearer picture of long‑term impact.
One concern raised was the need to balance efficacy with safety, especially given glucagon’s role in glucose regulation. Experts agreed that ongoing safety monitoring in the Phase 3 programs will be essential before wider adoption.
From a practical standpoint, the dual agonist could simplify treatment algorithms that currently rely on multiple drugs for weight management, glycemic control, and liver disease. This could reduce pill burden and improve adherence, though real‑world data will be needed to confirm those advantages.
The development of agents like survodutide reflects a shift toward therapies that target the metabolic syndrome as a whole rather than isolated components.
Related: User Blocked by Social Media Platform
For patients facing obesity, non‑alcoholic steatohepatitis (NASH), type 2 diabetes, and cardiovascular risk, a single medication that mitigates several risk factors could change clinical practice.
Overall, the panel emphasized that upcoming results from LEVERAGE and LEVERAGE Cirrhosis will determine whether the surrogate imaging findings translate into meaningful reductions in liver‑related events.
Future episodes will explore related topics, including an endocrinologist’s perspective on the interconnected nature of obesity, metabolic dysfunction, and cardiovascular disease.
Advances in this area are closely watched.
